{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:15:48Z","timestamp":1790104548017,"version":"4.0.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006537","name":"Campus France","doi-asserted-by":"publisher","award":["141628W"],"award-info":[{"award-number":["141628W"]}],"id":[{"id":"10.13039\/501100006537","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French National Institute of Cancer","award":["05-2011"],"award-info":[{"award-number":["05-2011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10549-025-07840-1","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T08:57:39Z","timestamp":1765184259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Side effects and adherence trajectories of adjuvant endocrine therapy in breast cancer patients: results from the VICAN2 study"],"prefix":"10.1007","volume":"215","author":[{"given":"Eqbal","family":"Radwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Memoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lor\u00e8ne","family":"Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-D\u00e9borah","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"7840_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69:363\u2013385. https:\/\/doi.org\/10.3322\/caac.21565","journal-title":"CA Cancer J Clin"},{"key":"7840_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","journal-title":"JAMA"},{"key":"7840_CR3","volume-title":"Breast cancer facts and figures 2017\u20132018 Atlanta","author":"Society AC","year":"2017","unstructured":"Society AC (2017) Breast cancer facts and figures 2017\u20132018 Atlanta. American Cancer Society, Inc"},{"key":"7840_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","volume":"20","author":"MB Lustberg","year":"2023","unstructured":"Lustberg MB, Kuderer NM, Desai A et al (2023) Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol 20:527\u2013542. https:\/\/doi.org\/10.1038\/s41571-023-00776-9","journal-title":"Nat Rev Clin Oncol"},{"key":"7840_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","volume":"62","author":"I Yussof","year":"2022","unstructured":"Yussof I, Tahir NAM, Hatah E et al (2022) Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. Breast 62:22\u201335. https:\/\/doi.org\/10.1016\/j.breast.2022.01.012","journal-title":"Breast"},{"key":"7840_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134:459\u2013478. https:\/\/doi.org\/10.1007\/s10549-012-2114-5","journal-title":"Breast Cancer Res Treat"},{"key":"7840_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s40064-016-2136-2","volume":"5","author":"O Ates","year":"2016","unstructured":"Ates O, Soylu C, Babacan T et al (2016) Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. Springerplus 5:486. https:\/\/doi.org\/10.1186\/s40064-016-2136-2","journal-title":"Springerplus"},{"key":"7840_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s12529-020-09908-2","volume":"27","author":"JM Jacobs","year":"2020","unstructured":"Jacobs JM, Walsh EA, Park ER et al (2020) The patient\u2019s voice: adherence, symptoms, and distress related to adjuvant endocrine therapy after breast cancer. Int J Behav Med 27:687\u2013697. https:\/\/doi.org\/10.1007\/s12529-020-09908-2","journal-title":"Int J Behav Med"},{"key":"7840_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-013-2422-4","volume":"138","author":"L Huiart","year":"2013","unstructured":"Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138:325\u2013328. https:\/\/doi.org\/10.1007\/s10549-013-2422-4","journal-title":"Breast Cancer Res Treat"},{"key":"7840_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.2024.42.16_suppl.537","volume":"42","author":"F Chino","year":"2024","unstructured":"Chino F, Chino JP, Thom B et al (2024) Patient-reported provider communication skills and adherence to recommended treatment in breast cancer. J Clin Oncol 42:537. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.537","journal-title":"J Clin Oncol"},{"key":"7840_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/1078155212455939","volume":"19","author":"M Danilak","year":"2013","unstructured":"Danilak M, Chambers CR (2013) Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract 19:105\u2013110. https:\/\/doi.org\/10.1177\/1078155212455939","journal-title":"J Oncol Pharm Pract"},{"key":"7840_CR12","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Kushi LH, Shao T et al (2011) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28:4120\u20134128. https:\/\/doi.org\/10.1200\/JCO.2009.25.9655","journal-title":"J Clin Oncol"},{"key":"7840_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.18553\/jmcp.2019.25.5.578","volume":"25","author":"VB Sheppard","year":"2019","unstructured":"Sheppard VB, He J, Sutton A et al (2019) Adherence to adjuvant endocrine therapy in insured black and white breast cancer survivors: exploring adherence measures in patient data. J Manag Care Spec Pharm 25:578\u2013586. https:\/\/doi.org\/10.18553\/jmcp.2019.25.5.578","journal-title":"J Manag Care Spec Pharm"},{"key":"7840_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-clinpsy-081122-012416","volume":"20","author":"DS Nagin","year":"2024","unstructured":"Nagin DS, Jones BL, Elmer J (2024) Recent advances in group-based trajectory modeling for clinical research. Annu Rev Clin Psychol 20:285\u2013305. https:\/\/doi.org\/10.1146\/annurev-clinpsy-081122-012416","journal-title":"Annu Rev Clin Psychol"},{"key":"7840_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/pds.4012","volume":"25","author":"AN Winn","year":"2016","unstructured":"Winn AN, Dusetzina SB (2016) The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf 25:953\u2013959. https:\/\/doi.org\/10.1002\/pds.4012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7840_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10549-020-05549-x","volume":"180","author":"L Lambert-C\u00f4t\u00e9","year":"2020","unstructured":"Lambert-C\u00f4t\u00e9 L, Bouhnik AD, Bendiane MK et al (2020) Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. Breast Cancer Res Treat 180:777\u2013790. https:\/\/doi.org\/10.1007\/s10549-020-05549-x","journal-title":"Breast Cancer Res Treat"},{"key":"7840_CR17","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/j.clbc.2021.01.007","volume":"21","author":"G Lailler","year":"2021","unstructured":"Lailler G, Memoli V, Benjamin CLB et al (2021) Five-year adjuvant endocrine therapy adherence trajectories among women with breast cancer: a nationwide French study using administrative data. Clin Breast Cancer 21:e415\u2013e426. https:\/\/doi.org\/10.1016\/j.clbc.2021.01.007","journal-title":"Clin Breast Cancer"},{"key":"7840_CR18","unstructured":"Institut national du cancer. (2014). La vie deux ans apr\u00e8s un diagnostic de cancer: De l\u2019annonce \u00e0 l\u2019apr\u00e8s cancer (Collection \u00c9tudes et enqu\u00eates). INCa."},{"key":"7840_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005971","volume":"5","author":"AD Bouhnik","year":"2015","unstructured":"Bouhnik AD, Bendiane MK, Cortaredona S et al (2015) The labour market, psychosocial outcomes and health conditions in cancer survivors: protocol for a nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey). BMJ Open 5:e005971. https:\/\/doi.org\/10.1136\/bmjopen-2014-005971","journal-title":"BMJ Open"},{"key":"7840_CR20","unstructured":"Institut national du cancer, Haute Autorit\u00e9 de sant\u00e9 (2010) Guide ALD 30\u2014Tumeur maligne, affection maligne du tissu lymphatique ou h\u00e9matopo\u00ef\u00e9tique\u2014Cancer du sein. France."},{"key":"7840_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/j.1745-9125.2005.00026.x","volume":"43","author":"DS Nagin","year":"2005","unstructured":"Nagin DS, Tremblay RE (2005) Developmental trajectory groups: fact or a useful statistical fiction? Criminology 43:873\u2013904. https:\/\/doi.org\/10.1111\/j.1745-9125.2005.00026.x","journal-title":"Criminology"},{"key":"7840_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000360229","volume":"65","author":"DS Nagin","year":"2014","unstructured":"Nagin DS (2014) Group-based trajectory modeling: an overview. Ann Nutr Metab 65:205\u2013210. https:\/\/doi.org\/10.1159\/000360229","journal-title":"Ann Nutr Metab"},{"key":"7840_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0049124101029003005","volume":"29","author":"BL Jones","year":"2001","unstructured":"Jones BL, Nagin DS, Roeder K (2001) A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methodol 29:374\u2013393. https:\/\/doi.org\/10.1177\/0049124101029003005","journal-title":"Sociol Methodol"},{"key":"7840_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13058-024-01819-4","volume":"26","author":"KM Woolpert","year":"2024","unstructured":"Woolpert KM, Schmidt JA, Ahern TP et al (2024) Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients. Breast Cancer Res 26:59. https:\/\/doi.org\/10.1186\/s13058-024-01819-4","journal-title":"Breast Cancer Res"},{"key":"7840_CR25","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1200\/JCO.23.02643","volume":"42","author":"JA Schmidt","year":"2024","unstructured":"Schmidt JA, Woolpert KM, Hjorth CF et al (2024) Social characteristics and adherence to adjuvant endocrine therapy in premenopausal women with breast cancer. J Clin Oncol 42:3300\u20133307. https:\/\/doi.org\/10.1200\/JCO.23.02643","journal-title":"J Clin Oncol"},{"key":"7840_CR26","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1007\/s00520-020-05585-9","volume":"28","author":"O AlOmeir","year":"2020","unstructured":"AlOmeir O, Patel N, Donyai P (2020) Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory. Support Care Cancer 28:5075\u20135084. https:\/\/doi.org\/10.1007\/s00520-020-05585-9","journal-title":"Support Care Cancer"},{"key":"7840_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/11782234241240171","volume":"18","author":"C Aurell","year":"2024","unstructured":"Aurell C, Haidar A, Giglio D (2024) Follow-up routines matter for adherence to endocrine therapy in the adjuvant setting of breast cancer. Breast Cancer Basic Clin Res 18:11782234241240171. https:\/\/doi.org\/10.1177\/11782234241240171","journal-title":"Breast Cancer Basic Clin Res"},{"key":"7840_CR28","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/jamaoncol.2016.1291","volume":"2","author":"AI Neugut","year":"2016","unstructured":"Neugut AI, Zhong X, Wright JD et al (2016) Nonadherence to medications for chronic conditions and nonadherence to adjuvant hormonal therapy in women with breast cancer. JAMA Oncol 2:1326\u20131332. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1291","journal-title":"JAMA Oncol"},{"key":"7840_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv202","volume":"107","author":"NC Llarena","year":"2015","unstructured":"Llarena NC, Estevez SL, Tucker SL, Jeruss JS (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst 107:djv202. https:\/\/doi.org\/10.1093\/jnci\/djv202","journal-title":"J Natl Cancer Inst"},{"key":"7840_CR30","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1768::AID-CNCR19>3.0.CO;2-O","volume":"86","author":"LB Wenzel","year":"1999","unstructured":"Wenzel LB, Fairclough DL, Brady MJ, Cella D, Garrett KM, Kluhsman BC, Marcus AC (1999) Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer 86:1768\u20131774","journal-title":"Cancer"},{"key":"7840_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12905-025-03870-5","volume":"25","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Gao W, Li X et al (2025) Motherhood role concerns in young women with breast cancer: a mixed-methods study. BMC Womens Health 25:313. https:\/\/doi.org\/10.1186\/s12905-025-03870-5","journal-title":"BMC Womens Health"},{"key":"7840_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1200\/JCO.2016.68.2807","volume":"35","author":"AJ Farias","year":"2017","unstructured":"Farias AJ, Du XL (2017) Association between out-of-pocket costs, race\/ethnicity, and adjuvant endocrine therapy adherence among Medicare patients with breast cancer. J Clin Oncol 35:86\u201395. https:\/\/doi.org\/10.1200\/JCO.2016.68.2807","journal-title":"J Clin Oncol"},{"key":"7840_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25345","volume":"5","author":"N Sood","year":"2022","unstructured":"Sood N, Liu Y, Lian M et al (2022) Association of endocrine therapy initiation timeliness with adherence and continuation in low-income women with breast cancer. JAMA Netw Open 5:e2225345. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25345","journal-title":"JAMA Netw Open"},{"key":"7840_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-018-4890-z","volume":"172","author":"W Wulaningsih","year":"2018","unstructured":"Wulaningsih W, Garmo H, Ahlgren J et al (2018) Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Res Treat 172:167\u2013177. https:\/\/doi.org\/10.1007\/s10549-018-4890-z","journal-title":"Breast Cancer Res Treat"},{"key":"7840_CR35","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1200\/JCO.2013.49.6489","volume":"31","author":"AA Aizer","year":"2013","unstructured":"Aizer AA, Chen MH, McCarthy EP et al (2013) Marital status and survival in patients with cancer. J Clin Oncol 31:3869\u20133876. https:\/\/doi.org\/10.1200\/JCO.2013.49.6489","journal-title":"J Clin Oncol"},{"key":"7840_CR36","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1200\/JCO.2013.51.5080","volume":"31","author":"DW Kissane","year":"2013","unstructured":"Kissane DW (2013) Marriage is as protective as chemotherapy in cancer care. J Clin Oncol 31:3852\u20133853. https:\/\/doi.org\/10.1200\/JCO.2013.51.5080","journal-title":"J Clin Oncol"},{"key":"7840_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2019.101706","volume":"44","author":"C Clancy","year":"2020","unstructured":"Clancy C, Lynch J, O\u2019Connor P et al (2020) Breast cancer patients\u2019 experiences of adherence and persistence to oral endocrine therapy: a qualitative evidence synthesis. Eur J Oncol Nurs 44:101706. https:\/\/doi.org\/10.1016\/j.ejon.2019.101706","journal-title":"Eur J Oncol Nurs"},{"key":"7840_CR38","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1002\/cam4.2352","volume":"8","author":"Z Zhai","year":"2019","unstructured":"Zhai Z, Zhang F, Zheng Y et al (2019) Effects of marital status on breast cancer survival by age, race, and hormone receptor status: a population-based study. Cancer Med 8:4906\u20134917. https:\/\/doi.org\/10.1002\/cam4.2352","journal-title":"Cancer Med"},{"key":"7840_CR39","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.2165\/00151234-200905820-00016","volume":"27","author":"G Kimmick","year":"2009","unstructured":"Kimmick G, Anderson R, Camacho F et al (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27:3445\u20133451. https:\/\/doi.org\/10.2165\/00151234-200905820-00016","journal-title":"J Clin Oncol"},{"key":"7840_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/jwh.2014.4982","volume":"24","author":"CJ Ursem","year":"2015","unstructured":"Ursem CJ, Bosworth HB, Shelby RA et al (2015) Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. J Womens Health 24:403\u2013408. https:\/\/doi.org\/10.1089\/jwh.2014.4982","journal-title":"J Womens Health"},{"key":"7840_CR41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40674","volume":"15","author":"S Nayyar","year":"2023","unstructured":"Nayyar S, Chakole S, Taksande AB et al (2023) From awareness to action: a review of efforts to reduce disparities in breast cancer screening. Cureus 15:e40674. https:\/\/doi.org\/10.7759\/cureus.40674","journal-title":"Cureus"},{"issue":"5","key":"7840_CR42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1080\/00981389.2019.1587661","volume":"58","author":"S Lilliehorn","year":"2019","unstructured":"Lilliehorn S, Isaksson J, Salander P (2019) What does an oncology social worker deal with in patient consultations?\u2013an empirical study. Soc Work Health Care 58(5):494\u2013508. https:\/\/doi.org\/10.1080\/00981389.2019.1587661","journal-title":"Soc Work Health Care"},{"issue":"3","key":"7840_CR43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/19371918.2021.1999878","volume":"37","author":"AA Agha","year":"2022","unstructured":"Agha AA, Onalu C, Chidebe R (2022) Bridging the gap: investigating the role of social workers in supporting metastatic breast cancer patients in Nigeria. Soc Work Public Health 37(3):244\u2013257. https:\/\/doi.org\/10.1080\/19371918.2021.1999878","journal-title":"Soc Work Public Health"},{"key":"7840_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13721","volume":"31","author":"AM Janssen","year":"2022","unstructured":"Janssen AM, Dam J, Prins J et al (2022) Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors\u2019 adherence to adjuvant endocrine therapy: an intervention mapping approach. Eur J Cancer Care 31:e13721. https:\/\/doi.org\/10.1111\/ecc.13721","journal-title":"Eur J Cancer Care"},{"key":"7840_CR45","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.3390\/healthcare11243181","volume":"11","author":"L Brajkovi\u0107","year":"2023","unstructured":"Brajkovi\u0107 L, Milat-Pan\u017ea K, Kopila\u0161 V (2023) Subjective well-being in cancer patients: the roles of social support, purpose in life, resilience, and informativeness. Healthcare 11:3181. https:\/\/doi.org\/10.3390\/healthcare11243181","journal-title":"Healthcare"},{"key":"7840_CR46","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.2147\/PPA.S440148","volume":"17","author":"M Pezzolato","year":"2023","unstructured":"Pezzolato M, Spada GE, Fragale E et al (2023) Predictive models of psychological distress, quality of life, and adherence to medication in breast cancer patients: a scoping review. Patient Prefer Adherence 17:3461\u20133473","journal-title":"Patient Prefer Adherence"},{"key":"7840_CR47","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00520-011-1242-5","volume":"20","author":"GH de Bock","year":"2012","unstructured":"de Bock GH, Musters RF, Bos HJ et al (2012) Psychotropic medication during endocrine treatment for breast cancer. Support Care Cancer 20:1533\u20131540. https:\/\/doi.org\/10.1007\/s00520-011-1242-5","journal-title":"Support Care Cancer"},{"key":"7840_CR48","doi-asserted-by":"publisher","DOI":"10.1590\/1518-8345.2258.2958","volume":"25","author":"RR Villar","year":"2017","unstructured":"Villar RR, Fern\u00e1ndez SP, Garea CC et al (2017) Quality of life and anxiety in women with breast cancer before and after treatment. Rev Latinoam Enferm 25:e2958. https:\/\/doi.org\/10.1590\/1518-8345.2258.2958","journal-title":"Rev Latinoam Enferm"},{"key":"7840_CR49","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/pon.5672","volume":"30","author":"MJ Lee","year":"2021","unstructured":"Lee MJ, Huang CW, Lee CP et al (2021) Investigation of anxiety and depressive disorders and psychiatric medication use before and after cancer diagnosis. Psychooncology 30:919\u2013927. https:\/\/doi.org\/10.1002\/pon.5672","journal-title":"Psychooncology"},{"key":"7840_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.clbc.2024.07.005","volume":"24","author":"SL Su\u00e1rez","year":"2024","unstructured":"Su\u00e1rez SL, Crespo ME, S\u00e1nchez JMB, de la Muela MH (2024) Immediate psychological implications of risk-reducing mastectomies in women with increased risk of breast cancer: a comparative study. Clin Breast Cancer 24:620\u2013629. https:\/\/doi.org\/10.1016\/j.clbc.2024.07.005","journal-title":"Clin Breast Cancer"},{"key":"7840_CR51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12032-009-9181-4","volume":"27","author":"O Karakoyun-Celik","year":"2010","unstructured":"Karakoyun-Celik O, Gorken I, Sahin S et al (2010) Depression and anxiety levels in women under follow-up for breast cancer: relationship to coping with cancer and quality of life. Med Oncol 27:108\u2013113. https:\/\/doi.org\/10.1007\/s12032-009-9181-4","journal-title":"Med Oncol"},{"key":"7840_CR52","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1158\/1078-0432.CCR-20-3974","volume":"27","author":"LJ Collin","year":"2021","unstructured":"Collin LJ, Cronin-Fenton DP, Ahern TP et al (2021) Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women. Clin Cancer Res 27:1421\u20131428. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3974","journal-title":"Clin Cancer Res"},{"key":"7840_CR53","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/curroncol30020112","volume":"30","author":"R Rosso","year":"2023","unstructured":"Rosso R, D\u2019Alonzo M, Bounous VE et al (2023) Adherence to adjuvant endocrine therapy in breast cancer patients. Curr Oncol 30:1461\u20131472. https:\/\/doi.org\/10.3390\/curroncol30020112","journal-title":"Curr Oncol"},{"key":"7840_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13729","volume":"31","author":"S Davies","year":"2022","unstructured":"Davies S, Voutsadakis IA (2022) Adherence to adjuvant hormonal therapy in localised breast cancer. Eur J Cancer Care 31:e13729. https:\/\/doi.org\/10.1111\/ecc.13729","journal-title":"Eur J Cancer Care"},{"key":"7840_CR55","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","volume":"30","author":"NL Henry","year":"2012","unstructured":"Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936\u2013942. https:\/\/doi.org\/10.1200\/JCO.2011.38.0261","journal-title":"J Clin Oncol"},{"key":"7840_CR56","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2147\/PPA.S167004","volume":"12","author":"P Gao","year":"2018","unstructured":"Gao P, You L, Wu D et al (2018) Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement. Patient Prefer Adherence 12:887\u2013897. https:\/\/doi.org\/10.2147\/PPA.S167004","journal-title":"Patient Prefer Adherence"},{"key":"7840_CR57","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1200\/JCO.2014.59.3673","volume":"33","author":"W He","year":"2015","unstructured":"He W, Fang F, Varnum C et al (2015) Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol 33:2262\u20132269. https:\/\/doi.org\/10.1200\/JCO.2014.59.3673","journal-title":"J Clin Oncol"},{"key":"7840_CR58","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/jnci\/djad109","volume":"115","author":"F Balazard","year":"2023","unstructured":"Balazard F, Bertaut A, Bordet \u00c9 et al (2023) Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation. J Natl Cancer Inst 115:1099\u20131108. https:\/\/doi.org\/10.1093\/jnci\/djad109","journal-title":"J Natl Cancer Inst"},{"key":"7840_CR59","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","volume":"108","author":"JE Mortimer","year":"2008","unstructured":"Mortimer JE, Flatt SW, Parker BA et al (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421\u2013426. https:\/\/doi.org\/10.1007\/s10549-007-9612-x","journal-title":"Breast Cancer Res Treat"},{"key":"7840_CR60","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","volume":"30","author":"AR Ferreira","year":"2019","unstructured":"Ferreira AR, Di Meglio A, Pistilli B et al (2019) Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol 30:1784\u20131795. https:\/\/doi.org\/10.1093\/annonc\/mdz298","journal-title":"Ann Oncol"},{"key":"7840_CR61","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","volume":"9","author":"J Cuzick","year":"2008","unstructured":"Cuzick J, Sestak I, Cella D et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143\u20131148. https:\/\/doi.org\/10.1016\/S1470-2045(08)70259-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"7840_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-401","volume":"13","author":"K Chim","year":"2013","unstructured":"Chim K, Xie SX, Stricker CT et al (2013) Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 13(1):401. https:\/\/doi.org\/10.1186\/1471-2407-13-401","journal-title":"BMC Cancer"},{"key":"7840_CR63","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.57.1547","volume":"33","author":"ML Irwin","year":"2015","unstructured":"Irwin ML, Cartmel B, Gross CP et al (2015) Randomized exercise trial of aromatase inhibitor\u2013induced arthralgia in breast cancer survivors. J Clin Oncol 33:1104\u20131111. https:\/\/doi.org\/10.1200\/JCO.2014.57.1547","journal-title":"J Clin Oncol"},{"key":"7840_CR64","unstructured":"Dent S, DeValentin T, Vendermeer L et al (2006) Long-term toxicities in women with early-stage breast cancer treated with aromatase inhibitors: data from a tertiary care center. Breast Cancer Res Treat 100(Suppl 1):S190. Abstract 4057"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07840-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07840-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07840-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:38:54Z","timestamp":1767789534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07840-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7840"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07840-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. It received approval from the Institute of Public Health (ISP,\u00a0C11-63), the Advisory Committee on Information Processing in Material Research in the Field of Health (CCTIRS,\u00a011\u2013143), and the French Data Protection Agency (CNIL,\u00a0911290). The study does not contain personal information and has no commercial interests. All participants provided written informed consent prior to participation. Additionally, the manuscript does not include any characteristics that could be used to identify the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent prior to participation. Additionally, the manuscript does not include any characteristics that could be used to identify the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"30"}}